Evaluating the efficacy of carbetocin versus oxytocin for preventing intraoperative blood loss, early postpartum hemorrhage, and maintaining a favorable hemodynamic profile in lower segment cesarean section: A prospective observational study
Keywords:
Lower-segment caesarean section; Oxytocin; Carbetocin; Postpartum hemorrhage; Obstetric hemorrhageAbstract
Background: Postpartum hemorrhage (PPH) remains a significant concern in obstetric practice, contributing substantially to maternal morbidity and mortality worldwide. Uterine atony, characterized by inadequate uterine muscle tone, constitutes approximately 70% of PPH cases. The initial step in medical management involves the use of uterotonic agents such as oxytocin, ergot alkaloids, and prostaglandins. However, their use is compounded by the accompanying side effects, hence the need for uterotonic agents with relatively better pharmacokinetic and pharmacodynamic profile continues. Carbetocin may require less additional uterotonic administration to manage blood loss compared to oxytocin alone. Carbetocin has a significantly longer half-life than oxytocin, potentially leading to more sustained uterine contractions and reduced blood loss.
Aims and Objectives: The aim of this study was to compare the efficacy of carbetocin versus oxytocin in preventing intraoperative blood loss and their individual impact on hemodynamics.
Materials and Methods: A total of 360 patients were enrolled for the study, sample size was calculated using Cochran’s formula considering 95% confidence level, and 0.5 variability of proportions and a precision of 5%, with 180 patients in each group, using simple randomization technique, the patients in either group received their assigned drugs during lower segment cesarean section (LSCS). Both the groups were assessed in terms of hemodynamic profile, intraoperative blood loss, need for additional uterotonic agents, and blood transfusion.
Results: On comparing the data between carbetocin group and oxytocin group, the carbetocin group had less incidence of hypotension and tachycardia (P<0.001), less intraoperative blood loss (Group C: Group O, mean±SD mL; 328.7±72.59:435.9±99.08 [P<0.001]), and minimal use of additional uterotonic agents (P<0.001); however, the requirement of blood transfusion was comparable between the two groups (P=0.157).
Conclusions: Carbetocin is an effective alternative to conventionally used oxytocin in LSCS.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Asian Journal of Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- The journal holds copyright and publishes the work under a Creative Commons CC-BY-NC license that permits use, distribution and reprduction in any medium, provided the original work is properly cited and is not used for commercial purposes. The journal should be recognised as the original publisher of this work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
